Want to join the conversation?
$MRK 2Q15 Call: From an access perspective, BELSOMRA is now covered by commercial payers, representing over 100MM lives and a branded DTC campaign will be launched next week to enhance consumer awareness. KEYTRUDA is now the number one therapy used to treat melanoma in the US and KEYTRUDA will be launched in the EU.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.